Vivek Subbiah: Our paper on the development of PROTAC degraders of oncogenic RET protein
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper by him as co-author, titled “Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein” published on Journal of Medicinal Chemistry.
Authors: Yafeng Wang, Xueqing Hu, Shriya Pandey, Ujjwol Khatri, Tao Shen, Vivek Subbiah, Blaine H. M. Mooers, Ting Chao, Shaohui Wang, Huaxuan Yu, Xingmin Sun, Jie Wu, Jianfeng Cai
“Just published One more paper to wrap the amazing year for Precision Medicine. Pleased to share our paper on the development of PROTAC degraders of oncogenic RET protein.
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein – in the Journal of Medicinal Chemistry.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023